[go: up one dir, main page]

DE69740108D1 - MORAXELLA CATARRHALIS ANTIGENE USPA1 AND USPA2 - Google Patents

MORAXELLA CATARRHALIS ANTIGENE USPA1 AND USPA2

Info

Publication number
DE69740108D1
DE69740108D1 DE69740108T DE69740108T DE69740108D1 DE 69740108 D1 DE69740108 D1 DE 69740108D1 DE 69740108 T DE69740108 T DE 69740108T DE 69740108 T DE69740108 T DE 69740108T DE 69740108 D1 DE69740108 D1 DE 69740108D1
Authority
DE
Germany
Prior art keywords
uspa2
uspa1
antigene
moraxella catarrhalis
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69740108T
Other languages
German (de)
Inventor
Eric J Hansen
Christoph Aebi
Leslie D Cope
Isobel Maciver
Michael J Fiske
Ross Fredenburg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Wyeth LLC
University of Texas System
University of Texas at Austin
Original Assignee
Wyeth Holdings LLC
Wyeth LLC
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings LLC, Wyeth LLC, University of Texas System, University of Texas at Austin filed Critical Wyeth Holdings LLC
Application granted granted Critical
Publication of DE69740108D1 publication Critical patent/DE69740108D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.
DE69740108T 1996-12-20 1997-12-19 MORAXELLA CATARRHALIS ANTIGENE USPA1 AND USPA2 Expired - Lifetime DE69740108D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3359896P 1996-12-20 1996-12-20
PCT/US1997/023930 WO1998028333A2 (en) 1996-12-20 1997-12-19 USPA1 AND USPA2 ANTIGENS OF $i(MORAXELLA CATARRHALIS)

Publications (1)

Publication Number Publication Date
DE69740108D1 true DE69740108D1 (en) 2011-03-10

Family

ID=21871324

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69740108T Expired - Lifetime DE69740108D1 (en) 1996-12-20 1997-12-19 MORAXELLA CATARRHALIS ANTIGENE USPA1 AND USPA2

Country Status (11)

Country Link
US (6) US6310190B1 (en)
EP (1) EP0948625B1 (en)
JP (2) JP2001515467A (en)
KR (1) KR100615109B1 (en)
CN (1) CN1159441C (en)
AT (1) ATE497004T1 (en)
AU (2) AU746442B2 (en)
BR (1) BR9714160A (en)
CA (1) CA2274495C (en)
DE (1) DE69740108D1 (en)
WO (1) WO1998028333A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6440425B1 (en) * 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
MX343744B (en) * 1998-05-01 2016-11-22 J Craig Venter Inst Inc Neisseria meningitidis antigens and compositions.
GB9817824D0 (en) * 1998-08-14 1998-10-14 Smithkline Beecham Biolog Novel compounds
GB9820002D0 (en) * 1998-09-14 1998-11-04 Smithkline Beecham Biolog Novel compounds
GB9904559D0 (en) 1999-02-26 1999-04-21 Smithkline Beecham Biolog Novel compounds
WO2000061165A1 (en) * 1999-04-13 2000-10-19 Smithkline Beecham Corporation Conserved adhesin motif and methods of use thereof
ATE397666T1 (en) * 1999-05-24 2008-06-15 Glaxosmithkline Biolog Sa NEW COMPOUNDS FROM MORAXELLA CATARRHALIS
CN100473663C (en) 2000-02-28 2009-04-01 启龙股份公司 Heterologous expression of neisserial proteins
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
WO2002083710A2 (en) * 2001-04-13 2002-10-24 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
US7449302B2 (en) 2002-10-02 2008-11-11 The University Of Bristol, University Walk Therapeutic peptides
GB0222764D0 (en) * 2002-10-02 2002-11-06 Univ Bristol Therapeutic peptide
US7407672B2 (en) * 2002-11-04 2008-08-05 National Heart Center Composition derived from biological materials and method of use and preparation
WO2005099337A2 (en) * 2004-04-15 2005-10-27 The University Of Bristol Therapeutic peptides
PT1868645E (en) 2005-04-08 2012-05-17 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
ES2537274T3 (en) 2005-08-10 2015-06-05 Arne Forsgren Ab Interaction of Moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
WO2008029271A2 (en) 2006-02-27 2008-03-13 Gal Markel Ceacam based antibacterial agents
EP2047257A4 (en) * 2006-06-29 2011-11-16 Suomen Punainen Risti Veripalvelu NEW CELLULAR GLYCAN COMPOSITIONS
US9056094B2 (en) * 2007-11-02 2015-06-16 Nippon Zenyaku Kogyo Co., Ltd. Adjuvant
TW201302779A (en) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa Fusion protein and combination vaccine
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (en) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс PCV AND MYCOPLASMA HYOPNEUMONIA COMBINED VACCINE
UA114504C2 (en) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс PCV, MYCOPLASMA HYOPNEUMONIA AND PRRS COMBINED VACCINE
TW201620927A (en) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 USPA2 protein construct and use thereof
CN105203754B (en) * 2014-08-18 2017-02-01 董俊 Method and kit for fast detection of moraxella catarrhalis based on magnetic resolution and quantum dot labelling
WO2019034575A1 (en) * 2017-08-14 2019-02-21 Glaxosmithkline Biologicals Sa METHODS OF AMPLIFYING IMMUNE RESPONSES
GB201803692D0 (en) * 2018-03-08 2018-04-25 Glaxosmithkline Biologicals Sa Immunogenic composition
CN110540594B (en) * 2018-12-20 2021-05-11 湖北工业大学 Preparation method of latex microsphere immunochromatographic test paper based on surface protein of Moraxella catarrhalis
CN110540964A (en) * 2018-12-20 2019-12-06 湖北诺美华抗体药物技术有限公司 monoclonal antibody of surface protein of Moraxella catarrhalis and application thereof
EP4028771A1 (en) * 2019-09-11 2022-07-20 GlaxoSmithKline Biologicals S.A. Assay

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5552146A (en) * 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
US5279721A (en) 1993-04-22 1994-01-18 Peter Schmid Apparatus and method for an automated electrophoresis system
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella

Also Published As

Publication number Publication date
US7569683B2 (en) 2009-08-04
WO1998028333A3 (en) 1999-01-07
CN1251611A (en) 2000-04-26
US20090137788A1 (en) 2009-05-28
US7344724B2 (en) 2008-03-18
ATE497004T1 (en) 2011-02-15
AU746442B2 (en) 2002-05-02
EP0948625A2 (en) 1999-10-13
CA2274495C (en) 2009-06-02
US6310190B1 (en) 2001-10-30
JP2009142276A (en) 2009-07-02
EP0948625B1 (en) 2011-01-26
CN1159441C (en) 2004-07-28
US20050131221A1 (en) 2005-06-16
AU2011201228A1 (en) 2011-04-14
JP2001515467A (en) 2001-09-18
AU5720198A (en) 1998-07-17
US20090118486A1 (en) 2009-05-07
CA2274495A1 (en) 1998-07-02
KR20000057575A (en) 2000-09-25
BR9714160A (en) 2000-05-02
KR100615109B1 (en) 2006-08-22
US7288646B2 (en) 2007-10-30
US6753417B2 (en) 2004-06-22
US20050137131A1 (en) 2005-06-23
WO1998028333A2 (en) 1998-07-02
US20030032772A1 (en) 2003-02-13
US7576194B2 (en) 2009-08-18

Similar Documents

Publication Publication Date Title
DE69740108D1 (en) MORAXELLA CATARRHALIS ANTIGENE USPA1 AND USPA2
EA199800973A1 (en) POLYPEPTID BELKA-106 OF THE EXTERNAL MORAXELLA CATARRHALIS MEMBRANE, SEQUENCE OF THE GENE AND THEIR APPLICATION
EA199700248A1 (en) ESSENTIALLY DETERMINED PURIFIED SURFACE ANTIGEN OF PROTEIN NATURE NEISSERIA AND FRAGMENT OF THIS ANTIGEN
NO940502L (en) Methods and Mixtures for Useful Antigens of Moraxella Catarrhalis
BR9610872A (en) Moraxella Transferrin Receptor Protein
ATE215831T1 (en) MONOCLONAL ANTIBODIES THAT BIND TO THE TUMOR REPELLANT ANT PRECURSOR MAGE-1, RECOMBINANT MAGE-1, AND IMMUNOGENIC PEPTIDES DISTRIBUTED FROM MAGE-1
DK0861261T3 (en) Nucleotide and protein sequences of vertebrate Delta genes and methods based thereon
EA200601715A1 (en) GETTING HUMANIZED ANTIBODIES IN [ORGANISM] OF TRANSGENIC ANIMALS
DE60238993D1 (en) HYBRID AND TANDEM PROTEINS FROM NEISSERIA SP
DE69330643D1 (en) MONOCLONAL ANTIBODY, WHICH SPECIFICALLY BINDS TO VASCULARIZED TUMOR DOTHELIUM AND USES THEREOF
SE9500418L (en) New attenuated Pseudomonas aerugionos strains
NO996514L (en) Surface antigens and proteins useful in compositions for diagnosis and prevention of Lyme disease
ATE112783T1 (en) STRESS PROTEIN FROM BACTERIA.
RU2004108115A (en) RECOMBINANT ANTIBODIES AND COMPOSITIONS, AND ALSO WAYS OF THEIR CREATION AND USE
SE9600434L (en) Fusion protein, bacteriophage expressing the protein, their use and hybridoma cells and monoclonals produced by the cells
DK0493446T3 (en) Treatment of autoimmune disease.
CA2137280A1 (en) Cloning of gene encoding the gp28.5 protein of toxoplasma gondii; peptide fragments of said protein and their applications
ATE154244T1 (en) INDUCING PROTECTION AGAINST VIRAL INFECTIONS
ATE246002T1 (en) MEMBRANE PROTEINS OF LEPTOSPIRA
ATE549348T1 (en) THERAPEUTIC PEPTIDES DERIVED FROM USPA1
Nakao et al. Monoclonal Antibodies against the Third Component (C 3) of Carp Complement
DK0470989T3 (en) Use of monoclonal anti-beta2 microglobulin antibodies
MX9709851A (en) Neutralizing conformational epitopes of chicken anemia virus.